Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis.
作者： Vasilios Pergialiotis , Elina Pitsouni , Anastasia Prodromidou , Maximos Frountzas , Despina N Perrea
DOI: 10.1097/GME.0000000000000508
关键词:
摘要: Objective Hormone therapy (HT) alleviates menopausal symptoms, but there is a lack of consensus regarding its use among premenopausal ovarian cancer survivors. Methods We systematically reviewed the literature and searched Medline (1966-2014), Scopus (2004-2014), Popline (1974-2014), ClinicalTrials.gov (2008-2014), Cochrane Central Register Controlled Trials CENTRAL (1999-2014) databases reference lists electronically retrieved studies. Statistical meta-analysis was performed using RevMan 5.1 software. Results Six studies were included in our systematic review, which involved 1,521 women. Among them, 451 women (29.6%) received HT, whereas remaining 1,070 (70.4%) did not receive any treatment. noticed statistically significant reduction cancer-related deaths who HT (odds ratio, 0.47; 95% CI, 0.28-0.80); however, disease recurrence rates differ between two groups 0.71; 0.45-1.14). Studies present review report difference overall survival disease-free receiving controls. Conclusions Based on results meta-analysis, does influence odds recurrence; this conclusion must be confirmed separately because limitations methodological quality included.
sci-hub.se 参考文章(32)
Writing Group for the Women's Health Initiative Investigators, Writing Group for the Women's Health Initiative Investigators, None, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial JAMA. ,vol. 288, pp. 321- 333 ,(2002) , 10.1001/JAMA.288.3.321
Rebecca DerSimonian, Raghu Kacker, Random-effects model for meta-analysis of clinical trials: An update Contemporary Clinical Trials. ,vol. 28, pp. 105- 114 ,(2007) , 10.1016/J.CCT.2006.04.004
Gillian K Reeves, Valerie Beral, Jane Green, Toral Gathani, Diana Bull, Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis Lancet Oncology. ,vol. 7, pp. 910- 918 ,(2006) , 10.1016/S1470-2045(06)70911-1
J Ryan, J Scali, I Carrière, H Amieva, O Rouaud, C Berr, K Ritchie, M-L Ancelin, Impact of a premature menopause on cognitive function in later life British Journal of Obstetrics and Gynaecology. ,vol. 121, pp. 1729- 1739 ,(2014) , 10.1111/1471-0528.12828
LI LI, ZHONGMIAN PAN, KUN GAO, WEI ZHANG, YUAN LUO, ZHONGQIANG YAO, XINQIANG LIANG, BUJIAN TANG, QINGDI QUENTIN LI, Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy. Oncology Letters. ,vol. 3, pp. 244- 249 ,(2012) , 10.3892/OL.2011.461
Alejandro R. Jadad, R.Andrew Moore, Dawn Carroll, Crispin Jenkinson, D.John M. Reynolds, David J. Gavaghan, Henry J. McQuay, Assessing the quality of reports of randomized clinical trials : is blinding necessary? Controlled Clinical Trials. ,vol. 17, pp. 1- 12 ,(1996) , 10.1016/0197-2456(95)00134-4
R A Eeles, S Tan, E Wiltshaw, I Fryatt, R P A'Hern, J H Shepherd, C L Harmer, P R Blake, C E Chilvers, Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ. ,vol. 302, pp. 259- 262 ,(1991) , 10.1136/BMJ.302.6771.259
Y. Wen, H. Huang, H. Huang, M. Wu, K. Shen, L. Pan, The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China Climacteric. ,vol. 16, pp. 673- 681 ,(2013) , 10.3109/13697137.2013.806472
Chantal Mascarenhas, Mats Lambe, Rino Bellocco, Kjell Bergfeldt, Tomas Riman, Ingemar Persson, Elisabete Weiderpass, Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival International Journal of Cancer. ,vol. 119, pp. 2907- 2915 ,(2006) , 10.1002/IJC.22218
Bo Zhou, Qingmin Sun, Rihong Cong, Haijuan Gu, Naping Tang, Li Yang, Bin Wang, Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecologic Oncology. ,vol. 108, pp. 641- 651 ,(2008) , 10.1016/J.YGYNO.2007.12.003